Top

Journal of Cardiovascular Magnetic Resonance

Published in:

Open Access 01-12-2015 | Review

The diagnostic value of iron oxide nanoparticles for imaging of myocardial inflammation – quo vadis?

Authors: Michael Bietenbeck, Anca Florian, Udo Sechtem, Ali Yilmaz

Published in: Journal of Cardiovascular Magnetic Resonance | Issue 1/2015

Abstract

Cardiovascular magnetic resonance (CMR) is an integral part in the diagnostic work-up of cardiac inflammatory diseases. In this context, superparamagnetic iron oxide-based contrast agents can provide additional diagnostic information regarding the assessment of myocardial infarction and myocarditis. After intravenous administration, these nanoparticles are taken up by activated monocytes and macrophages, which predominantly accumulate in regions associated with inflammation as was successfully shown in recent preclinical studies. Furthermore, first clinical studies with a new iron oxide-complex that was clinically approved for the treatment of iron deficiency anaemia recently demonstrated a superior diagnostic value of iron oxide nanoparticles compared to gadolinium-based compounds for imaging of myocardial inflammation in patients with acute myocardial infarction. In this article, we outline the basic features of superparamagnetic iron oxide-based contrast agents and review recent studies using such nanoparticles for cardiac imaging in case of acute myocardial infarction as well as acute myocarditis. Moreover, we highlight the translational potential of these agents and possible research applications with regard to imaging and therapy.

Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012;110(1):159–73.PubMedCentralPubMedCrossRef

Marchant DJ, Boyd JH, Lin DC, Granville DJ, Garmaroudi FS, McManus BM. Inflammation in myocardial diseases. Circ Res. 2012;110(1):126–44.PubMedCrossRef

Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636–2648d.PubMedCrossRef

Sutton MGS, Sharpe N. Left Ventricular Remodeling After Myocardial Infarction: Pathophysiology and Therapy. Circulation. 2000;101(25):2981–8.PubMedCrossRef

Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. JACC Cardiovasc Imaging. 2009;53(17):1475–87.

Seward JB, Casaclang-Verzosa G. Infiltrative cardiovascular diseases: cardiomyopathies that look alike. JACC. 2010;55(17):1769–79.PubMedCrossRef

Yilmaz A, Klingel K, Kandolf R, Sechtem U. Imaging in inflammatory heart disease: from the past to current clinical practice. Hellenic J Cardiol. 2009;50(6):449–60.PubMed

Mahrholdt H. Reproducibility of Chronic Infarct Size Measurement by Contrast-Enhanced Magnetic Resonance Imaging. Circulation. 2002;106(18):2322–7.PubMedCrossRef

Mewton N, Thuny F, Croisille P. T(2)-weighted CMR: but where is Elvis in the end? JACC Cardiovasc Imaging. 2012;5(2):233–4.PubMedCrossRef

10.

Friedrich MG, Kim HW, Kim RJ. T2-weighted imaging to assess post-infarct myocardium at risk. JACC Cardiovasc Imaging. 2011;4(9):1014–21.PubMedCentralPubMedCrossRef

11.

Yilmaz A, Ferreira V, Klingel K, Kandolf R, Neubauer S, Sechtem U. Role of cardiovascular magnetic resonance imaging (CMR) in the diagnosis of acute and chronic myocarditis. Heart Fail Rev. 2013;18(6):747–60.PubMedCrossRef

12.

Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001;11(11):2319–31.PubMedCrossRef

13.

Wang YX. Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application. Quant Imaging Med Surg. 2011;1(1):35–40.PubMedCentralPubMed

14.

Björnerud A, Johansson L. The utility of superparamagnetic contrast agents in MRI: theoretical consideration and applications in the cardiovascular system. NMR Biomed. 2004;17(7):465–77.PubMedCrossRef

15.

Yang Y, Yang Y, Yanasak N, Schumacher A, Hu TCC. Temporal and noninvasive monitoring of inflammatory-cell infiltration to myocardial infarction sites using micrometer-sized iron oxide particles. Magn Reson Med. 2010;63(1):33–40.PubMed

16.

Ittrich H, Peldschus K, Raabe N, Kaul M, Adam G. Superparamagnetic iron oxide nanoparticles in biomedicine: applications and developments in diagnostics and therapy. RöFo. 2013;185(12):1149–66.PubMed

17.

Lam T, Pouliot P, Avti PK, Lesage F, Kakkar AK. Superparamagnetic iron oxide based nanoprobes for imaging and theranostics. Adv Colloid Interface Sci. 2013;199–200:95–113.PubMedCrossRef

18.

Laurent S, Forge D, Port M, Roch A, Robic C, Vander EL, et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev. 2008;108(6):2064–110.PubMedCrossRef

19.

Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26(18):3995–4021.PubMedCrossRef

20.

Tassa C, Shaw SY, Weissleder R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc Chem Res. 2011;44(10):842–52.PubMedCentralPubMedCrossRef

21.

van Vlerken LE, Vyas TK, Amiji MM. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res. 2007;24(8):1405–14.PubMedCrossRef

22.

Ye F, Laurent S, Fornara A, Astolfi L, Qin J, Roch A, et al. Uniform mesoporous silica coated iron oxide nanoparticles as a highly efficient, nontoxic MRI T(2) contrast agent with tunable proton relaxivities. Contrast Media Mol Imaging. 2012;7(5):460–8.PubMedCrossRef

23.

Sahoo Y, Goodarzi A, Swihart MT, Ohulchanskyy TY, Kaur N, Furlani EP, et al. Aqueous ferrofluid of magnetite nanoparticles: Fluorescence labeling and magnetophoretic control. J Phys Chem B. 2005;109(9):3879–85.PubMedCrossRef

24.

Sahoo Y, Pizem H, Fried T, Golodnitsky D, Burstein L, Sukenik CN, et al. Alkyl phosphonate/phosphate coating on magnetite nanoparticles: A comparison with fatty acids. Langmuir. 2001;17(25):7907–11.CrossRef

25.

Jung CW. Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging. 1995;13(5):675–91.PubMedCrossRef

26.

Lu AH, Salabas EL, Schuth F. Magnetic nanoparticles: synthesis, protection, functionalization, and application. Angew Chem Int Ed Engl. 2007;46(8):1222–44.PubMedCrossRef

27.

Krishnan KM. Biomedical Nanomagnetics: A Spin Through Possibilities in Imaging, Diagnostics, and Therapy. IEEE Trans Mag. 2010;46(7):2523–58.CrossRef

28.

Salazar-Alvarez G, Muhammed M, Zagorodni AA. Novel flow injection synthesis of iron oxide nanoparticles with narrow size distribution. Chem Eng Sci. 2006;61(14):4625–33.CrossRef

29.

Kimata M, Nakagawa D, Hasegawa M. Preparation of monodisperse magnetic particles by hydrolysis of iron alkoxide. Powder Technol. 2003;132(2):112–8.CrossRef

30.

Chin AB, Yaacob II. Synthesis and characterization of magnetic iron oxide nanoparticles via w/o microemulsion and Massart’s procedure. J Mater Process Technol. 2007;191(1):235–7.CrossRef

31.

Stirrat CG, Newby DE, Robson JMJ, Jansen M. The Use of Superparamagnetic Iron Oxide Nanoparticles to Assess Cardiac Inflammation. Curr Cardiovasc Imaging Rep. 2014;7(5):9263.CrossRef

32.

Sun C, Lee JSH, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev. 2008;60(11):1252–65.PubMedCentralPubMedCrossRef

33.

Bean CP, Livingston JD. Superparamagnetism. J Appl Phys 1959;30(4):120–129.

34.

Weissleder R, Nahrendorf M, Pittet MJ. Imaging macrophages with nanoparticles. Nat Mater. 2014;13(2):125–38.PubMedCrossRef

35.

Owens DE, Peppas N. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93–102.PubMedCrossRef

36.

Singh N, Jenkins GJ, Asadi R, Doak SH. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev. 2010;1.

37.

Thorek DL, Tsourkas A. Size, charge and concentration dependent uptake of iron oxide particles by non-phagocytic cells. Biomaterials. 2008;29(26):3583–90.PubMedCentralPubMedCrossRef

38.

Weinstein JS, Varallyay CG, Dosa E, Gahramanov S, Hamilton B, Rooney WD, et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab. 2010;30(1):15–35.PubMedCentralPubMedCrossRef

39.

Wunderbaldinger P, Josephson L, Weissleder R. Crosslinked iron oxides (CLIO): a new platform for the development of targeted MR contrast agents. Acad Radiol. 2002;9 Suppl 2:S304–6.PubMedCrossRef

40.

Bethesda. Molecular Imaging and Contrast Agent Database (MICAD). 2006.

41.

Neuberger T, Schöpf B, Hofmann H, Hofmann M, Von Rechenberg B. Superparamagnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system. J Magn Magn Mat. 2005;293(1):483–96.CrossRef

42.

Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 2000;60(23):6641–8.PubMed

43.

Arruebo M, Fern + índez-Pacheco R, Ibarra MR, Js S ¡a. Magnetic nanoparticles for drug delivery. Nano Today. 2007;2(3):22–32.CrossRef

44.

Huang Z, Shen Y, Sun A, Huang G, Zhu H, Huang B, et al. Magnetic targeting enhances retrograde cell retention in a rat model of myocardial infarction. J Stem Cell Res Ther. 2013;4(6):149.CrossRef

45.

Fröhlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine. 2012;7:5577.PubMedCentralPubMedCrossRef

46.

Karlsson HL, Cronholm P, Gustafsson J, Moller L. Copper oxide nanoparticles are highly toxic: a comparison between metal oxide nanoparticles and carbon nanotubes. Chem Res Toxicol. 2008;21(9):1726–32.PubMedCrossRef

47.

Thoeny HC, Triantafyllou M, Birkhaeuser FD, Froehlich JM, Tshering DW, Binser T, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol. 2009;55(4):761–9.PubMedCrossRef

48.

Lu M, Cohen MH, Rieves D, Pazdur R. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol. 2010;85(5):315–9.PubMed

49.

Anzai Y, Piccoli CW, Outwater EK, Stanford W, Bluemke DA, Nurenberg P, et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology. 2003;228(3):777–88.PubMedCrossRef

50.

Chapon C, Franconi F, Lemaire L, Marescaux L, Legras P, Saint-Andre JP, et al. High field magnetic resonance imaging evaluation of superparamagnetic iron oxide nanoparticles in a permanent rat myocardial infarction. Invest Radiol. 2003;38(3):141–6.PubMed

51.

Sosnovik DE, Nahrendorf M, Deliolanis N, Novikov M, Aikawa E, Josephson L, et al. Fluorescence tomography and magnetic resonance imaging of myocardial macrophage infiltration in infarcted myocardium in vivo. Circulation. 2007;115(11):1384–91.PubMedCrossRef

52.

Montet-Abou K, Daire JL, Hyacinthe JNl, Jorge-Costa M, Grosdemange K, Mach F, et al. In vivo labelling of resting monocytes in the reticuloendothelial system with fluorescent iron oxide nanoparticles prior to injury reveals that they are mobilized to infarcted myocardium. Eur Heart J 2009;ehp547

53.

Protti A, Dong X, Andia ME, Yu B, Dokukina K, Chaubey S, et al. Assessment of inflammation with a very small iron-oxide particle in a murine model of reperfused myocardial infarction. J Magn Reson Imaging. 2014;39(3):598–608.PubMedCrossRef

54.

Moon H, Park HE, Kang J, Lee H, Cheong C, Lim YT, et al. Noninvasive assessment of myocardial inflammation by cardiovascular magnetic resonance in a rat model of experimental autoimmune myocarditis. Circulation. 2012;125(21):2603–12.PubMedCrossRef

55.

Yilmaz A, Rösch S, Klingel K, Kandolf R, Helluy X, Hiller KH, et al. Magnetic resonance imaging (MRI) of inflamed myocardium using iron oxide nanoparticles in patients with acute myocardial infarction - preliminary results. Int J Cardiol. 2013;163(2):175–82.PubMedCrossRef

56.

Alam SR, Shah ASV, Richards J, Lang NN, Barnes G, Joshi N, et al. Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction: early clinical experience. Circ Cardiovasc Imaging. 2012;5(5):559–65.PubMedCrossRef

57.

Yilmaz A, Dengler M, van der Kuip H, Yildiz H, Rösch S, Klumpp S, et al. Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanoparticles: a human study using a multi-parametric cardiovascular magnetic resonance imaging approach. Eur Heart J. 2013;34(6):462–75.PubMedCrossRef

58.

Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation. 2010;121(22):2437–45.PubMedCentralPubMedCrossRef

59.

Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science. 2013;339(6116):161–6.PubMedCentralPubMedCrossRef

60.

Cheng K, Shen D, Hensley MT, Middleton R, Sun B, Liu W, et al. Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting. Nat Commun. 2014;5:4880. doi: 10.1038/ncomms5880.

61.

Boyer C, Whittaker MR, Bulmus V, Liu JQ, Davis TP. The design and utility of polymer-stabilized iron-oxide nanoparticles for nanomedicine applications. NPG Asia Mater. 2010;2(1):23–30.CrossRef

62.

Richards JM, Shaw CA, Lang NN, Williams MC, Semple SI, MacGillivray TJ, et al. In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: feasibility and safety in humans. Circ Cardiovasc Imaging. 2012;5(4):509–17.PubMedCrossRef

Title: The diagnostic value of iron oxide nanoparticles for imaging of myocardial inflammation – quo vadis?
Authors: Michael Bietenbeck
Anca Florian
Udo Sechtem
Ali Yilmaz
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Journal of Cardiovascular Magnetic Resonance / Issue 1/2015
Electronic ISSN: 1532-429X
DOI: https://doi.org/10.1186/s12968-015-0165-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The diagnostic value of iron oxide nanoparticles for imaging of myocardial inflammation – quo vadis?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Pulmonary artery to aorta ratio for the detection of pulmonary hypertension: cardiovascular magnetic resonance and invasive hemodynamics in heart failure with preserved ejection fraction

2D cine DENSE with low encoding frequencies accurately quantifies cardiac mechanics with improved image characteristics

Influence of phase correction of late gadolinium enhancement images on scar signal quantification in patients with ischemic and non-ischemic cardiomyopathy

Cardiovascular magnetic resonance findings in patients with PRKAG2 gene mutations

Distribution of abnormal potentials in chronic myocardial infarction using a real time magnetic resonance guided electrophysiology system

Increased pericardial fat accumulation is associated with increased intramyocardial lipid content and duration of highly active antiretroviral therapy exposure in patients infected with human immunodeficiency virus: a 3T cardiovascular magnetic resonance feasibility study